Drug Interactions Newsletter

Volume 2, Issue 46, 12/01/2010

Question

Can the use of proton pump inhibitors (PPI) decrease the absorption (or bioavailability) of oral iron replacement in patients with iron deficiency anemia?

Answer

Chronic use of proton pump inhibitors (PPI) has increased over the past decade due to their efficacy in treating a number of gastrointestinal conditions such as peptic ulcer disease, gastroesophageal reflux disease, Zollinger-Ellison Syndrome, helicobacter pylori infections, to name a few.  However, continuous use may expose the patient to adverse effects and/or clinically relevant drug-drug interactions.(1)  The current PPIs on the market include dexlansoprazole (Kapidex), esomeprazole (Nexium), omeprazole (Prilosec; Zegerid), lansoprazole (Prevacid), pantoprazole (Protonix), and rabeprazole (AcipHex).  One area of concern that has been discussed for decades is the need for adequate...

.......To read the full answer please LOGIN or SUBSCRIBE NOW.